The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Both drugs were given on top of standard antidepressants to patients wo had failed a least two earlier treatments. Spravato has been approved since 2019 for TRD, with its label extended the ...

Spravato (esketamine) is prescribed for adults to treat: major depressive disorder (MDD), also called depression, with suicidal thoughts or actions treatment-resistant depression For MDD ...

Esketamine, the S isomer of ketamine, has already gained approval for treatment-resistant depression under the trademark Spravato; psilocybin and ketamine have been shown to provide benefits to ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid epidemic?

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

My practice is integrated care for adults (psychiatric medication management, psychedelic esketamine (Spravato) treatments, primary care, weight loss injection therapy and asthetics). I am board ...

Blessing Outpatient Behavioral Health Services is offering a new option for depression. As many as 40% of people with depression can find no relief for their condition.

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

So SPRAVATO is indicated for treatment resistant depression. It is esketamine. It's a single enantiomer of ketamine. It's an intranasally administered compound. It was approved in 2019 for ...